Oral [spco]
17 beta-Estradiol [horm, phsu, strd]
Combined [qlco]
Dydrogesterone [horm, phsu, strd]
lowers [spco]
serum concentration [qnco]
Lipoprotein (a) [aapp, bacs]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Lipoprotein (a) [aapp, bacs]
Lp(a) [aapp, bacs]
Independent [idcn]
Atherosclerosis [dsyn]
serum concentration [qnco]
Lp(a) [aapp, bacs]
Menopause [phsf]
postmenopausal [tmco]
Estrogen Replacement [topp]
APPEAR [qlco]
Decrease [qlco]
Lp(a) [aapp, bacs]
randomized [resa]
Double-Blind Study [resa]
Examined [fndg]
effects [qlco]
treatment [ftcn]
Daily [tmco]
17 beta-Estradiol [horm, phsu, strd]
mg% [qnco]
Orally [spco]
Combined [qlco]
Dosages [qnco]
2 5 [qnco]
mg% [qnco]
N NOS [aapp, imft]
mg% [qnco]
N NOS [aapp, imft]
mg% [qnco]
N NOS [aapp, imft]
mg% [qnco]
N NOS [aapp, imft]
Dydrogesterone [horm, phsu, strd]
Fasting [fndg]
serum concentration [qnco]
Lp(a) [aapp, bacs]
Health [idcn]
postmenopausal [tmco]
Women [popg]
baseline [bodm]
Note [clna]
treatment [ftcn]
Group [idcn]
Study [mnob]
months [tmco]
serum concentration [qnco]
Lp(a) [aapp, bacs]
Decreased [qnco]
mg/L [qnco]
Range [qnco]
mg/L [qnco]
Range [qnco]
Total population [qnco]
reduction [npop]
P NOS [aapp, imft]
Percent [qnco]
Lp(a) [aapp, bacs]
Correlated [qlco]
Percent [qnco]
months [tmco]
therapy [ftcn]
R- [spco]
P NOS [aapp, imft]
R- [spco]
P NOS [aapp, imft]
Dose [qnco]
Response [orga]
Dydrogesterone [horm, phsu, strd]
Lp(a) [aapp, bacs]
Addition [ftcn]
Serum lipids NOS [lbpr]
Lipoproteins [aapp, bacs]
Improved [qlco]
treatment [ftcn]
Group [idcn]
Oral [spco]
Combined [qlco]
Dydrogesterone [horm, phsu, strd]
effects [qlco]
Lipid [lipd]
Lipoprotein [aapp, bacs]
Profile [lbpr]
effective [qlco]
lowering [spco]
Lp(a) [aapp, bacs]
Concentrations [menp]
postmenopausal [tmco]
Women [popg]
